Severe COVID-19 Illness and α1-Antitrypsin Deficiency: COVID-AATD Study
Tóm tắt
Background: Epidemiologic studies have reported that the geographical distribution of the prevalence of allelic variants of serine protein inhibitor-A1 (SERPINA1) and severe cases of COVID-19 were similar. Methods: A multicenter, cross-sectional, observational study to evaluate the frequency of alpha-1 antitrypsin deficiency (AATD) in patients with COVID-19 and whether it was associated with having suffered severe COVID-19. Results: 2022 patients who had laboratory-confirmed SARS-CoV-2 infection. Mutations associated with AATD were more frequent in severe COVID versus non-severe (23% vs. 18.8%, p = 0.022). The frequency of Pi*Z was 37.8/1000 in severe COVID versus 17.5/1000 in non-severe, p = 0.001. Having an A1AT level below 116 was more frequent in severe COVID versus non-severe (29.5% vs. 23.1, p = 0.003). Factors associated with a higher likelihood of severe COVID-19 were being male, older, smoking, age-associated comorbidities, and having an A1AT level below 116 mg/dL [OR 1.398, p = 0.003], and a variant of the SERPINA1 gene that could affect A1AT protein [OR 1.294, p = 0.022]. Conclusions: These observations suggest that patients with AATD should be considered at a higher risk of developing severe COVID-19. Further studies are needed on the role of A1AT in the prognosis of SARS-CoV-2 infection and its possible therapeutic role.
Từ khóa
Tài liệu tham khảo
World Health Organization (2022, September 28). WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/.
McElvaney, 2020, Characterization of the Inflammatory Response to Severe COVID-19 Illness, Am. J. Respir. Crit. Care Med., 202, 812, 10.1164/rccm.202005-1583OC
Yamamoto, N., Yamamoto, R., Ariumi, Y., Mizokami, M., Shimotohno, K., and Yoshikura, H. (2021). Does Genetic Predisposition Contribute to the Exacerbation of COVID-19 Symptoms in Individuals with Comorbidities and Explain the Huge Mortality Disparity between the East and the West?. Int. J. Mol. Sci., 22.
Simons, 2020, Presence of Genetic Variants Among Young Men with Severe COVID-19, Jama, 324, 663, 10.1001/jama.2020.13719
McCoy, K., Peterson, A., Tian, Y., and Sang, Y. (2020). Immunogenetic Association Underlying Severe COVID-19. Vaccines, 8.
Calle Rubio, M., Soriano, J.B., López-Campos, J.L., Soler-Cataluña, J.J., Alcázar Navarrete, B., Rodríguez González-Moro, J.M., Miravitlles, M., Barrecheguren, M., Ferrer, M.E.F., and Hermosa, J.L.R. (2018). Testing for alpha-1 antitrypsin in COPD in outpatient respiratory clinics in Spain: A multilevel, cross-sectional analysis of the EPOCONSUL study. PLoS ONE, 13.
Shapira, 2020, Ethnic differences in alpha-1 antitrypsin deficiency allele frequencies may partially explain national differences in COVID-19 fatality rates, FASEB J., 34, 14160, 10.1096/fj.202002097
Wettstein, 2021, Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection, Nat. Commun., 12, 1726, 10.1038/s41467-021-21972-0
Azouz, 2021, Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2-Priming Protease TMPRSS2, Pathog. Immun., 6, 55, 10.20411/pai.v6i1.408
Wang, 2020, An anti-oxidative therapy for ameliorating cardiac injuries of critically ill COVID-19-infected patients, Int. J. Cardiol., 312, 137, 10.1016/j.ijcard.2020.04.009
Petrache, 2006, Alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis, Am. J. Pathol., 169, 1155, 10.2353/ajpath.2006.060058
WHO Working Group on the Clinical Characterisation, and Management of COVID-19 infection (2020). A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect. Dis., 20, e192–e197.
Carrascosa, 2021, Results of a diagnostic procedure based on multiplex technology on dried blood spots and buccal swabs for subjects with suspected alpha1 antitrypsin deficiency, Arch. Bronconeumol., 57, 42
Janciauskiene, 2020, Serum Levels of Alpha1-antitrypsin and their relationship with COPD in the General Spanish Population, Arch. Bronconeumol., 56, 76, 10.1016/j.arbres.2019.03.001
Yoshikura, 2021, Epidemiological correlation between COVID-19 epidemic and prevalence of α-1 antitrypsin deficiency in the world, Glob. Health Med., 3, 73, 10.35772/ghm.2020.01068
Ferrarotti, 2021, COVID-19 infection in severe Alpha 1-antitrypsin deficiency: Looking for a rationale, Respir. Med., 183, 106440, 10.1016/j.rmed.2021.106440
Faria, 2021, Alpha-1 antitrypsin deficiency severity and the risk of COVID-19: A Portuguese cohort, Respir. Med., 181, 106387, 10.1016/j.rmed.2021.106387
Parr, 2022, Impact of COVID-19 in Patients with Severe Alpha-1 Antitrypsin Deficiency: The IMCA1 Study of the EARCO Clinical Research Collaboration, Arch. Bronconeumol., 58, 840, 10.1016/j.arbres.2022.07.002
Schneider, 2021, SARS-CoV-2 infection in alpha1-antitrypsin deficiency, Respir. Med., 184, 106466, 10.1016/j.rmed.2021.106466
Blanco, 2017, Alpha-1 antitrypsin Pi*SZ genotype: Estimated prevalence and number of SZ subjects worldwide, Int. J. Chronic Obstr. Pulm. Dis., 12, 1683, 10.2147/COPD.S137852
2022, Long-term Outcomes and Recovery of Patients who Survived COVID-19: LUNG INJURY COVID-19 Study, Open Forum Infect. Dis., 9, ofac098, 10.1093/ofid/ofac098
Corton, 2022, Presence of rare potential pathogenic variants in subjects under 65 years old with very severe or fatal COVID-19, Sci. Rep., 12, 10369, 10.1038/s41598-022-14035-x
2020, Histopathology and genetic susceptibility in COVID-19 pneumonia, Eur. J. Clin. Investig., 50, e13259, 10.1111/eci.13259
Zhou, 2020, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study, Lancet, 395, 1054, 10.1016/S0140-6736(20)30566-3
Guan, 2020, China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis, Eur. Respir. J., 55, 2000547, 10.1183/13993003.00547-2020
Gassen, 2019, SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-Coronavirus infection, Nat. Commun., 10, 5770, 10.1038/s41467-019-13659-4
Oguntuyo, K.Y., Stevens, C.S., Siddiquey, M.N., Schilke, R.M., Woolard, M.D., Zhang, H., Acklin, J.A., Ikegame, S., Huang, C.-T., and Lim, J.K. (2020). In plain sight: The role of alpha-1-antitrypsin in COVID-19 pathogenesis and therapeutics. bioRxiv, Preprint.
Bergin, 2014, The circulating proteinase inhibitor α-1 antitrypsin regulates neutrophil degranulation and autoimmunity, Sci. Transl. Med., 6, 217ra1, 10.1126/scitranslmed.3007116
Berman, 2016, alpha1-Antitrypsin reduces rinovirus infection in primary human airway epithelial cells exposed to cigarette smoke, Int. J. Chronic Obstr. Pulm. Dis., 11, 1279, 10.2147/COPD.S105717
Stephenson, 2017, Impact of HIV infection on α1-antitrypsin in the lung, Am. J. Physiol. Lung Cell. Mol. Physiol., 314, L583, 10.1152/ajplung.00214.2017
Hashemi, 2005, High prevalence of Alpha 1 antitrypsin phenotypes in viral hepatitis B infected patients in Iran, Hepatol. Res., 33, 292, 10.1016/j.hepres.2005.09.035
Ishii, 2010, Neutrophil elastase contributes to acute lung injury induced by bilateral nephrectomy, Am. J. Pathol., 177, 1665, 10.2353/ajpath.2010.090793
McCarthy, 2018, Glycosylation Repurposes Alpha-1 Antitrypsin for Resolution of Community-acquired Pneumonia, Am. J. Respir. Crit. Care Med., 197, 1346, 10.1164/rccm.201709-1954LE
Janciauskiene, 2007, Alpha1-antitrypsin, old dog, new tricks. Alpha1-antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevating cAMP, J. Biol. Chem., 282, 8573, 10.1074/jbc.M607976200
McElvaney, 2020, Consequences of Abrupt Cessation of Alpha1-Antitrypsin Replacement Therapy, N. Engl. J. Med., 382, 1478, 10.1056/NEJMc1915484